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Abstract
Background: Patients with metastatic renal cell carcinoma (mRCC) treated with targeted systemic therapies have
demonstrated favourable outcomes in randomised controlled trials, however real-world evidence is limited. Thus,
this study aimed to determine the effectiveness of targeted systemic therapies for patients with mRCC in routine
clinical practice in the UK.
Methods: A retrospective, observational, longitudinal study based on chart review of newly diagnosed adult mRCC
patients treated at two UK hospitals from 2008 to 2015 was conducted. Targeted systemic therapies recommended
for use in mRCC patients were evaluated across first to third lines of therapy (1LOT-3LOT). Important exclusions
were treatment with cytokine therapy and within non-standard of care clinical trials. Primary outcome measure was
overall survival (OS); data were analysed descriptively and using Kaplan-Meyer analysis.
Results: 652 patients (65.3% male, 35.0% ≥70 years) were included. In 1LOT, 98.5% of patients received sunitinib or
pazopanib. In 2LOT and 3LOT, 99.0 and 94.4% received axitinib or everolimus. Median OS was 12.9, 6.5 and 5.9
months at 1LOT, 2LOT and 3LOT respectively. Estimated OS at 1-year was 52.4% (95% CI: 48.6–56.4%) in 1LOT,
31.5% (25.2–39.5%) in 2LOT and 23.8% (10.1–55.9%) in 3LOT. Median OS from 1LOT in favourable, intermediate and
poor MSKCC were 39.7, 15.8 and 6.1 months respectively.
Conclusions: In this study, treatment was consistent with current National Institute for Health and Care Excellence
(NICE) guidelines for mRCC patients. Although the study population favoured poorer prognosis patients, outcomes
were more favourable than those for England at the same time. However, overall survival in this ‘real-world’
population remains poor and indicates significant unmet need for effective and safe treatment options to improve
survival among mRCC patients.
Keywords: Renal Cancer, Molecular targeted therapy, Survival analysis
© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated in a credit line to the data.
* Correspondence: robert.e.hawkins@manchester.ac.uk
1University of Manchester and The Christie Hospital, Manchester, UK
Full list of author information is available at the end of the article
Hawkins et al. BMC Cancer          (2020) 20:670 
https://doi.org/10.1186/s12885-020-07154-z
Background
Kidney cancer is the seventh most common cancer in
the UK, accounting for 3% of all new cancer diagnoses
[1]. Among all forms of kidney cancer, renal cell carcin-
oma (RCC) accounts for more than 80% of cases. Fur-
thermore, 25–31% of UK patients have metastatic RCC
(mRCC) at initial diagnosis. Five-year survival rates of
RCC vary greatly depending on the stage of the disease,
decreasing from 82 to 84% in patients with stage I dis-
ease to 5.2–6.6% in those with stage IV [1]. Recurrence
rates are also significant, with up to 60% of patients who
have undergone surgical intervention for localised dis-
ease experiencing a relapse within 5 years of nephrec-
tomy [2]. Therefore, the number of patients requiring
treatment for advanced and/or metastatic disease is
substantial.
Cytokine therapy with interleukin-2 (IL-2) or
interferon-alpha (IFN-α) had been the standard ap-
proach to treating mRCC patients for over 20 years.
However, poor response rates, marginal survival benefit
and significant toxicity [3] prompted the development of
alternative treatment options for the majority of patients.
As the understanding of the molecular biology under-
lying RCC has increased, specific molecular targets have
been identified for potential therapies. These molecular-
targeted therapies have improved efficacy and tolerability
over cytokine therapy, and subsequently several targeted
therapies have become available for first- and second-
line use.
Targeted systemic therapies have been associated with
significant improvements in progression-free survival
(PFS) and, in some cases, overall survival (OS), better
quality of life and a lower incidence of adverse events
(AEs), compared to cytokine therapy [3–10]. However,
outcomes from tightly controlled clinical trials are not
always reflective of routine clinical practice, thus, there
is a need to generate evidence on the real-world effect-
iveness of treatments for patients with mRCC.
This study aimed to determine the real-world effect-
iveness of treatments for patients with mRCC by de-
scribing the clinical characteristics and outcomes of
patients treated with targeted systemic therapies in rou-
tine UK clinical practice based on contemporaneous
data collected from two large hospitals.
Methods
Patients
A retrospective, observational, longitudinal cohort study
based on a chart review was undertaken for newly diag-
nosed mRCC patients treated with systemic therapies at
two UK hospitals (Addenbrooke’s Hospital, Cambridge
and The Christie Hospital, Manchester). Patients were
included if they were initially diagnosed with mRCC
(index date) without concomitant malignant tumours
between 01 January 2008 and 31 December 2015, were ≥
18 years at the index date, had complete treatment infor-
mation available and were followed up until death or the
end of follow-up (31 December 2016). Patients were ex-
cluded if they satisfied one or more of the following cri-
teria: a) not treated exclusively with NICE/cancer drug
fund (CDF)-recommended systemic therapies that tar-
geted receptors and signalling pathways involved in as-
pects of the cell cycle; (b) took part in a clinical trial in
which the systemic therapies were not administered
within standard of care (SoC); or (c) lost to follow-up
(LTFU) prior to 30 June 2016. Patient consent was not
required because this study was a retrospective chart re-
view of anonymised data.
Data collection
An electronic case report form (eCRF) was used to cap-
ture demographic and clinical data on eligible patients at
baseline, including: age at index date; ethnicity; relevant
comorbidities in the year prior to index date; Eastern
Cooperative Oncology Group (ECOG); performance
score (PS); Memorial Sloan Kettering Cancer Centre
(MSKCC) risk score [11, 12] and histological subtype.
Information on treatment patterns, including treatment
prescribed in each line of therapy (LOT), the number
(first/second/third) line of therapy (1LOT/2LOT/3LOT
respectively), treatment initiation and discontinuation
dates, reason for treatment discontinuation, treatment
holiday, change in dose and AE incidence were gathered
from medical records. The principal endpoint was OS,
defined for each LOT as time from treatment initiation
to death or most recent medical record. This was further
stratified by treatment regimen, age, MSKCC score and
histological subtype. All data were anonymised at a site
level to ensure patient confidentiality before being sent
for pooled analyses. The MSKCC risk score was re-
calculated at this time to ensure across-site alignment.
The study complied with the International Society for
Pharmacoepidemiology (ISPE) Guidelines for Good
Pharmacoepidemiology Practices (GPP) [13] and applic-
able regulatory requirements. All required approvals
from Ethics Committees, Independent Review Commit-
tees, Regulatory Authorities, and/or other local govern-
ance bodies were obtained.
Data transformation
Only targeted systemic therapies recommended by the
National Institute for Health and Care Excellence (NICE)
for use in this patient population were evaluated. At the
time of analysis (April, 2019), NICE supported the use of
cabozantinib, tivozanib, pazopanib and sunitinib as first-
line treatments (1LOT) in patients with advanced or meta-
static RCC [14]. At second-line (2LOT), everolimus, axi-
tinib, nivolumab, cabozantinib, and lenvatinib (combined
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with everolimus) were supported. Treatment pathways
agreed by NICE indicate that approved 2LOT treatments
are also used for third-line therapy (3LOT) [15].
To align with NICE-recommended pathways, patients
were kept within 1LOT for analysis if they switched
from sunitinib to pazopanib (or vice versa). Start date,
clinical characteristics and risk scores pertaining to the
regimen that they were switched from were assigned to
the LOT in question, while discontinuation date (if ap-
plicable) and outcomes were related to the regimen the
patient was subsequently treated with. Discontinuation
of the switched-to regimen defined the end of 1LOT. Pa-
tients who proceeded to receive other treatment were
considered as moving onto a subsequent LOT.
MSKCC scores [11, 12] at 1LOT and 2 + LOT were
calculated post-study and a point accrued for matching
each of the following criteria: 1) Karnosfky PS < 80; 2)
calcium ≥2.5 mmol/L; 3) haemoglobin < 13.5/12.0 g/dL
(male/female); 4) (1LOT only) days since RCC diagnosis
≤365; 5) (1LOT only) lactate dehydrogenase (LDH) > 1.5
times the upper limit of normal (i.e. 369 IU/L and 825
IU/L for Cambridge and Manchester, respectively). Risk
classifications for 1LOT/2 + LOT were: Favourable: 0/0;
Intermediate: 1–2/1; Poor: 3–5/2–3.
Statistical analysis
Baseline patient demographic and clinical characteristics
were analysed descriptively. There was no specific re-
search hypothesis pertaining to OS and therefore no for-
mal sample size calculations were required with respect to
statistical power. OS estimates and other time-to-event
variables were determined using Cox multivariate propor-
tional hazards models and Kaplan-Meier analysis methods
with log-rank and Wilcoxon tests used to compare out-
comes, with significance level defined as p < 0.05. Confi-
dence interval (CI) was calculated using the Wilson Score
method for estimated proportions. All statistical analyses
were performed using R (version 3.4.2). Kaplan-Meier
curves were generated using R’s survival package.
Results
Patient population
Of the 840 patients who met the inclusion criteria, 188
were excluded because they satisfied one or more of the
following exclusion criteria: not treated exclusively with
NICE/CDF-recommended systemic therapies (n = 120,
67% of which received IL-2 or IFN-α therapy); partici-
pated in a clinical trial in which systemic therapies were
not administered within SoC (n = 72); or were LTFU
prior to 30 June 2016 (n = 29). Data from 652 patients
were included in the final analysis, with 424 (65.0%) and
228 (35.0%) patients from Manchester and Cambridge
respectively. Baseline characteristics are presented in
Table 1, patients were on average 64.8 years old,
predominantly male (65.3%) and white (96.5%). 79.5%
had clear-cell mRCC subtype, 30.7% of patients were
hypertensive and 12.0% had type 2 diabetes mellitus.
The percentage of patients with favourable, intermediate
and poor MSKCC scores at 1LOT were 11.2, 58.3 and
26.7% respectively.
Treatment patterns
All 652 included patients received treatment at 1LOT,
with the majority receiving sunitinib (60.7%) or pazopa-
nib (37.7%; Table 2). 8.9% of patients switched regimens
(5.7% from pazopanib to sunitinib and 3.2% from suniti-
nib to pazopanib; Supplementary Fig. 1, Additional File
1). One hundred eighty-four patients received treatment
at 2LOT, with the majority receiving axitinib (57.1%) or
everolimus (41.9%). Eighteen patients received treatment
at 3LOT; 72.2% received everolimus and 22.2% received
axitinib. No patients received treatment at 4LOT. Mean
(95% CI) follow up was 23.8 (22.2–25.4) months. 21.5,
26.1 and 33.3% of patients remained on 1LOT, 2LOT
and 3LOT treatments at follow-up respectively. Time to
events by LOT and adverse events by LOT are sum-
marised in Supplementary Table 1 and 2 (Additional File
1) respectively.
Overall survival
Median OS for all patients who received a 1LOT was 12.9
months from initiation, with a one-year survival estimate
of 52.4% (95% CI: 48.6–56.4%; Fig. 1). Median OS from
1LOT initiation increased to 20.8months and 36.7months
for those who received 2 + LOTs and 3LOTs respectively.
For those patients who received a 2LOT, median OS from
2LOT initiation was 6.5months with a one-year survival
estimate of 31.5% (95% CI: 25.2–39.5%)). Median OS from
3LOT initiation was 5.9months with a one-year survival
estimate of 23.8% (95% CI: 10.1–55.9%). Median OS from
initiation of 1LOT of the 89 excluded patients who re-
ceived either IL-2 or IFN-α at any point during the study
was 47.5months (Supplemental Fig. S3).
The effects of treatment regimen, age, MSKCC classifi-
cation (at treatment initiation), diagnosis date (pre 2012
(01 January 2008 to 31 December 2011)/post 2012 (01
January 2012 to 31 December 2015)), and histological sub-
type on OS for 1LOT and 2LOT are reported in Fig. 2
and Supplementary Fig. 2 (Additional File 1) respectively.
In both 1LOT and 2LOT, significant differences were ob-
served between OS and MSKCC classification (p < 0.001).
At both LOTs, favourable-risk patients achieved the best
survival outcomes (median OS; 1LOT – 39.7months;
2LOT – 14.3months), compared with intermediate-risk
(median OS; 1LOT – 15.8months; 2LOT – 8.9months)
and poor-risk patients (median OS; 1LOT – 6.1months;
2LOT – 3.3months). Furthermore, OS was higher in pa-
tients treated between 2012 and 15 (14.2months)
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comparted with those treated between 2008 and 11 (11.8
months). To validate inferences made, a Cox multivariate
proportional hazards model was implemented at both
1LOT and 2LOT. Inferences were consistent across the
two approaches.
Discussion
This retrospective, observational chart review study aimed
to determine the real-world effectiveness of common tar-
geted systemic therapies for patients with mRCC within
routine UK clinical practice. Baseline characteristics of the
Table 1 Baseline characteristics of patients included in the study
Characteristic Patients receiving 1LOT Patients receiving 2LOT Patients receiving 3LOT
Number of Patients 652 184 18
Centre
Cambridge 228 (35.0%) 58 (31.5%) 5 (27.8%)
Manchester 424 (65.0%) 126 (68.5%) 13 (72.2%)
Age at index, mean (SD) 64.84 (10.5) 62.97 (10.3) 65.06 (8.9)
< 70 years, n (%) 424 (65.0%) 130 (70.7%) 13 (72.2%)
≥ 70 years, n (%) 228 (35.0%) 54 (29.4%) 5 (27.8%)
Male, n (%) 426 (65.3%) 124 (67.4%) 14 (77.8%)
Weight (kg), mean (SD) 78.12 (17.5) 79.99 (17.8) 77.92 (12.6)
Missing, n (%) 243 (37.3%) 57 (31.0%) 6 (33.3%)
Histological subtype, n (%)
Clear cell 518 (79.5%) 141 (76.6%) 13 (72.2%)
Non-clear cell 70 (10.7%) 28 (15.2%) 4 (22.2%)
Other 22 (3.4%) 5 (2.7%) 1 (5.6%)
MSKCC prognostic risk score (at time of LOT initiation), n(%)
Favourable 73 (11.2%) 27 (14.7%) 2 (11.1%)
Intermediate 380 (58.3%) 77 (41.9%) 11 (61.1%)
Poor 174 (26.7%) 59 (32.1%) 2 (11.1%)
Missing 25 (3.8%) 21 (11.4%)
Ethnicity, n (%)
White 629 (96.5%) 176 (95.7%) 17 (94.4%)
Black 4 (0.6%) 2 (1.1%) 0 (0.0%)
Asian (Chinese/other) 1 (0.2%) 1 (0.5%) 0 (0.0%)
Asian (South-East Asian) 15 (2.3%) 5 (2.7%) 1 (5.6%)
Mixed 0 (0.0%) 0 (0.0%) 0 (0.0%)
Other 3 (0.5%) 0 (0.0%) 0 (0.0%)
Comorbidity (History of), n (%)
Hypertension 200 (30.7%) 55 (29.9%) 8 (44.4%)
T1DM 5 (0.8%) 1 (0.5%) 0 (0.0%)
T2DM 78 (12.0%) 27 (14.7%) 0 (0.0%)
CAD 29 (4.5%) 4 (2.2%) 0 (0.0%)
Congestive HF 4 (0.6%) 0 (0.0%) 0 (0.0%)
Hypothyroidism 21 (3.2%) 6 (3.3%) 1 (5.6%)
VTE 6 (0.9%) 1 (0.5%) 0 (0.0%)
Autoimmune disease 1 (0.2%) 0 (0.0%) 0 (0.0%)
Conditions involving regular corticosteroid therapy 5 (0.78%) 0 (0.0%) 0 (0.0%)
Other 229 (35.1%) 62 (33.7%) 5 (27.8%)
CAD Coronary Artery Disease, ECOG PS Eastern Cooperative Oncology Group Performance Status, HF Heart failure, MSKCC Memorial Sloan-Kettering Cancer Center,
SD Standard deviation, T1DM Type 1 diabetes mellitus, T2DM Type 2 diabetes mellitus, VTE Venus Thromboembolism
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study population were comparable to the demographics of
the UK renal cancer population in terms of sex and the
proportion of patients with clear cell mRCC [1], however
our cohort were notably younger than the average UK kid-
ney cancer population. In this study, only 35% of patients
were aged 70 and older, whereas UK statistics indicate
that approximately half of newly diagnosed patients are
≥70 years old [1]. This may be because the focus of this
study was on those newly diagnosed with mRCC (as op-
posed to non-metastatic RCC) and was limited to patients
treated with targeted systemic therapies.
During the study period (2008–2015), NICE technical
advisory guidance outlined recommendations for suniti-
nib (TA169) and pazopanib (TA215) at first line from
2009 and 2011 respectively, and for everolimus (TA219)
and axitinib (TA333) at second line from 2011 and 2015
respectively [14]. Treatment pathways agreed by NICE
Table 2 Treatments received by LOT
Treatment, n (%) 1LOT 2LOT 3LOT
Received treatment 652 184 18
Sunitinib 396 (60.7%) 1 (0.5%) –
Originally prescribed 375 (57.5%) 1 (0.5%) –
Pazopanib intolerant 21 (3.2%) – –
Pazopanib 246 (37.7%) – –
Originally prescribed 209 (32.1%) – –
Sunitinib intolerant 37 (5.7%) – –
Axitinib – 105 (57.1%) 4 (22.2%)
Everolimus 4 (0.6%) 77 (41.9%) 13 (72.2%)
Other 6 (0.9%) 1 (0.5%) 1 (5.6%)
On treatment at FU 140 (21.5%) 48 (26.1%) 6 (33.3%)
LOT Line of therapy, FU Follow-Up
Fig. 1 Overall survival by LOT. Shaded region denotes 95% confidence interval
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indicate that approved 2LOT therapies are also used for
3LOT [15]. Data were analysed in this study to align
with the NICE pathways for advanced and/or metastatic
RCC, therefore the received treatments were consistent
with NICE-recommended systemic therapies. The ma-
jority of patients in this study received sunitinib or pazo-
panib at 1LOT (98.5%) and everolimus and axitinib at
2LOT (99.0%) and 3LOT (94.4%).
Only 28% of 1LOT patients received a 2LOT, and only
3% of 1LOT patients received a 3LOT. Figures published
more recently (2012–2016) by one of the sites involved
in this study are 48 and 16% respectively [16], which
likely reflect the lower numbers of favourable prognosis
patients included in this study and an increase in avail-
able treatments over time. Indeed, since the beginning of
the study period, several newer therapies for mRCC
Fig. 2 Overall survival from 1LOT stratified by key baseline characteristics. a: By regimen; b: By Age; c: By MSKCC score; d: By Diagnosis Year; e: By
Histological Subtype (not shown)
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patients have been approved (i.e. tivozanib (TA512),
cabozantinib (TA542) and nivolumab with ipilimumab
(TA581) at 1LOT; lenvatinib with everolimus (TA498),
cabozantinib (TA463), and nivolumab (TA417) at 2 +
LOT) [14]. Furthermore, no patients received a 4LOT
treatment, which may reflect the fact that no fourth-line
treatments have been approved by NICE, therefore limit-
ing the therapeutic options for mRCC patients post-
3LOT.
Both 1-year and 5-year survival within the study
period (2008–2015) were higher than the available esti-
mates for England (from 2013 to 2015; 1 year: 52.4% vs
37.5% [17] and 5-year: 10.8% vs 5.2–6.6% [18]), and
comparable to a Swedish real-world study over a similar
period [19]. However, the OS observed in this study was
lower than that reported in an earlier retrospective
multi-centre UK database study (Renal Cell Carcinoma
Outcomes Research Dataset, RECCORD) [20], and in
real-world studies from other countries over a similar
timeframe [21–24]. The RECCORD study included only
patients with clear cell renal cancer (80% of our cohort),
and included patients on clinical trials and a small num-
ber of patients receiving IL-2 or IFN-α. Median age was
also younger (61 years). Subgroup analyses (Supplemen-
tary Fig. 3, Additional File 1) of the 89 patients excluded
from the main analysis because they received IL-2 or
IFN-α at any point during the study revealed a median
OS of almost four-times longer (47.5 vs. 12.9 months at
1LOT) than patients treated exclusively with NICE/
CDF-recommended systemic therapies and reflects the
fact that the Manchester Centre is a national treatment
centre for high-dose IL-2 which, in carefully selected pa-
tients, can have an excellent outcome [25]. In addition, a
further 72 patients were excluded because they partici-
pated in clinical trials where systemic therapies were not
administered within standard of care. These patients
were excluded as they would have biased OS in favour
of better outcomes and may partly explain the shorter
OS observed in this analysis compared with similar
studies.
Survival prognoses within the study were strongly
linked with MSKCC risk score. This method is a fre-
quently utilised [26] and validated [27, 28] scoring sys-
tem for prediction of patient survival and was reliable in
this cohort of mRCC patients. Favourable-risk patients
achieved a 6.6-fold increase in OS (compared with poor-
risk patients) at 1LOT and a 4.3-fold increase at 2LOT.
Although this association remained in 1LOT patients,
the improvement was somewhat diminished from 18
months onwards in the 2LOT cohort, probably reflecting
the lack of suitable subsequent approved therapies
within this disease area. It is however important to note
that all analyses are descriptive in nature and confound-
ing variables not controlled for. In this study, the
proportion of patients in the favourable risk category
was lower (11% vs 25%) and poor risk patients slightly
higher (27% vs 22%) compared with a reference mRCC
population [11]. This finding is likely due to variations
in the characteristics of the study populations and our
exclusion of patients receiving cytokine therapies from
the main analysis, who had significantly longer OS and
more favourable distribution of MSKCC scores.
The nature of real-world research means there is het-
erogeneity across treatments used at each LOT and
across patient characteristics involved in each study, and
therefore comparison between study outcomes should
be done with caution. Our study focused on patients for
whom a full medical history was available and had one
or more treatments, therefore becoming susceptible to
immortal time bias. Furthermore, participation was lim-
ited to two specialist RCC centres and inclusion was lim-
ited to patients who received NICE-recommended
targeted systemic therapies alone (not in conjunction
with cytokine therapy or within a clinical trial), therefore
it is unclear how generalisable the study findings are to
alternative patient populations or settings.
Despite the limitations associated with this study, in-
cluding the large numbers of excluded patients, the
study remains the largest real-world study on the treat-
ment patterns and outcomes of mRCC patients in the
UK. The study was limited to an assessment of the treat-
ment patterns and outcomes of patients receiving tar-
geted systemic therapies; however, with increasing use of
immunotherapy in recent years, the impact of this group
of therapies in the treatment of mRCC warrants investi-
gation in future studies.
Conclusions
In this real-world study, treatment was consistent with
current NICE guidelines for mRCC patients. Although
the study population was selected in favour of poorer
prognosis patients, and median OS was lower than that
that reported by a UK database study over a similar
period, both 1-year and 5-year survival outcomes in this
study were more favourable than those reported by other
studies in England at the same time. Overall, survival
outcomes in this ‘real world’ population remain poor
and indicates significant unmet need for effective and
safe treatment options which could improve survival
among mRCC patients.
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